Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Carrie A. Bohnert, MPA, Aaron W. Calhoun, MD, and Olivia F. Mittel, MD, MS
Research and training are needed so that physicians are able to identify human trafficking victims and refer them to appropriate trauma-informed treatment.
AMA J Ethics. 2017;19(1):35-42. doi:
10.1001/journalofethics.2017.19.1.ecas4-1701.
Patrick S. Phelan, Mary C. Politi, PhD, and Christopher J. Dy, MD, MPH
During immediate and long-term recovery periods, decisions must account for patients’ personal goals and possible clinical outcomes and should clarify what recovery means.
AMA J Ethics. 2020;22(5):E380-387. doi:
10.1001/amajethics.2020.380.
This article considers that benefits of using humor in clinical settings come with risks of diminishing therapeutic capacity in patient-clinician relationships.
AMA J Ethics. 2020;22(7):E576-582. doi:
10.1001/amajethics.2020.576.